Research graph
References from Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+. Local targets link to admitted publications; unresolved targets remain external evidence.
International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma
10.1016/s1470-2045(14)70442-5 · 2014 · External reference
Outlook: multiple myeloma
10.1038/d41586-020-03223-2 · 2020 · External reference
Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost
10.1007/s12185-020-02841-w · 2020 · External reference
Molecular basis of clonal evolution in multiple myeloma
10.1007/s12185-020-02829-6 · 2020 · External reference
Revised international staging system for multiple myeloma: a report from International Myeloma Working Group
10.1200/jco.2015.61.2267 · 2015 · External reference
Second revision of the International Staging System (R2-ISS) for overall survival in multiple myeloma: a European Myeloma Network (EMN) report within the HARMONY project
10.1200/jco.21.02614 · 2022 · External reference
The relative importance of factors predicting outcome for myeloma patients at different ages: results from 3894 patients in the Myeloma XI trial
10.1038/s41375-019-0595-5 · 2020 · External reference
Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): follow-up analysis of a randomised, phase 3 study
10.1016/s1470-2045(22)00019-5 · 2022 · External reference
Subgroup analysis of ICARIA-MM study in relapsed/refractory multiple myeloma patients with high-risk cytogenetics
10.1111/bjh.17499 · 2021 · External reference
Primary outcomes by 1q21+ status for isatuximab-treated patients with relapsed/refractory multiple myeloma: subgroup analyses from ICARIA-MM and IKEMA
10.3324/haematol.2022.280660 · 2022 · External reference
Plasma membrane proteomics identifies biomarkers associated with MMSET overexpression in t(4;14) multiple myeloma
10.18632/oncotarget.1049 · 2013 · External reference
MMSET regulates expression of IRF4 in t(4;14) myeloma and its silencing potentiates the effect of bortezomib
10.1038/leu.2015.169 · 2015 · External reference
MMSET: role and therapeutic opportunities in multiple myeloma
10.1155/2014/636514 · 2014 · External reference
NSD family proteins: rising stars as therapeutic targets
10.1016/j.cellin.2024.100151 · 2024 · External reference
Development of novel inhibitors for histone methyltransferase SET7/9 based on cyproheptadine
10.1002/cmdc.201800233 · 2018 · External reference
Identification of cyproheptadine as an inhibitor of SET domain containing lysine methyltransferase 7/9 (Set7/9) that regulates estrogen-dependent transcription
10.1021/acs.jmedchem.5b01732 · 2016 · External reference
The MMSET histone methyl transferase switches global histone methylation and alters gene expression in t(4;14) multiple myeloma cells
10.1182/blood-2010-07-298349 · 2011 · External reference
Eradication of central nervous system leukemia of T-cell origin with a brain-permeable LSD1 inhibitor
10.1158/1078-0432.ccr-18-0919 · 2019 · External reference
c-FOS mediates IMiDs resistance acting as a co-activator of IKZF1-target genes in multiple myeloma
10.1002/ctm2.1364 · 2023 · External reference
Phosphorylation-mediated EZH2 inactivation promotes drug resistance in multiple myeloma
10.1172/jci80325 · 2015 · External reference
mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation
10.3324/haematol.2021.278506 · 2021 · External reference
A trial of streptonigrin in the treatment of advanced malignant disease
10.1038/bjc.1967.32 · 1967 · External reference
High-throughput screening with nucleosome substrate identifies small-molecule inhibitors of the human histone lysine methyltransferase NSD2
10.1074/jbc.ra118.004274 · 2018 · External reference
Pharmacology and antitumor activity of a quinolinedione Cdc25 phosphatase inhibitor DA3003-1 (NSC 663284)
2007 · External reference
Point mutation E1099K in MMSET/NSD2 enhances its methyltranferase activity and leads to altered global chromatin methylation in lymphoid malignancies
10.1038/leu.2013.204 · 2014 · External reference
IRF4 addiction in multiple myeloma
10.1038/nature07064 · 2008 · External reference
Selective antisense oligonucleotide inhibition of human IRF4 prevents malignant myeloma regeneration via cell cycle disruption
10.1016/j.stem.2020.12.017 · 2021 · External reference
Histone methylation: a dynamic mark in health, disease and inheritance
10.1038/nrg3173 · 2012 · External reference
NSD2 overexpression drives clustered chromatin and transcriptional changes in a subset of insulated domains
10.1038/s41467-019-12811-4 · 2019 · External reference
Drug discovery targeting nuclear receptor binding SET domain protein 2 (NSD2)
10.1021/acs.jmedchem.3c00948 · 2023 · External reference
The histone methyltransferase and putative oncoprotein MMSET is overexpressed in a large variety of human tumors
10.1158/1078-0432.ccr-10-1302 · 2011 · External reference
AKT-mediated stabilization of histone methyltransferase WHSC1 promotes prostate cancer metastasis
10.1172/jci91144 · 2017 · External reference
Overexpression of MMSET may contribute to the progression of endometrial cancer and also may serve as a new biomarker to predict the prognosis of endometrial cancer
10.1002/jso.23234 · 2013 · External reference
S-adenosylhomocysteine hydrolase, S-adenosylmethionine, S-adenosylhomocysteine: correlations with ribavirin induced anemia
10.1016/j.mehy.2004.03.031 · 2004 · External reference
3-Deazaneplanocin A: a new inhibitor of S-adenosylhomocysteine synthesis and its effects in human colon carcinoma cells
10.1016/0006-2952(86)90774-4 · 1986 · External reference
DZNep is a global histone methylation inhibitor that reactivates developmental genes not silenced by DNA methylation
10.1158/1535-7163.mct-09-0013 · 2009 · External reference
Inhibition of nuclear receptor binding SET domain 2/multiple myeloma SET domain by LEM-06 implication for epigenetic cancer therapies
10.15430/jcp.2015.20.2.113 · 2015 · External reference
BIX-01294 inhibits oncoproteins NSD1, NSD2 and NSD3
10.1007/s00044-017-1909-7 · 2017 · External reference
Structure of the epigenetic oncogene MMSET and inhibition by N-alkyl sinefungin derivatives
10.1021/acschembio.6b00308 · 2016 · External reference
5-Aminonaphthalene derivatives as selective nonnucleoside nuclear receptor binding SET domain-protein 2 (NSD2) inhibitors for the treatment of multiple myeloma
10.1016/j.ejmech.2021.113592 · 2021 · External reference
SMARCA2 is a novel interactor of NSD2 and regulates prometastatic PTP4A3 through chromatin remodeling in t(4;14) multiple myeloma
10.1158/0008-5472.can-20-2946 · 2021 · External reference
Discovery of small-molecule antagonists of the PWWP domain of NSD2
10.1021/acs.jmedchem.0c01768 · 2021 · External reference
A chemical probe targeting the PWWP domain alters NSD2 nucleolar localization
10.1038/s41589-021-00898-0 · 2022 · External reference
